Becton Dickinson (BDX)

This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial results. These earnings calls are crucial events for investors, analysts, and the broader market, as they provide insights into corporate

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.

Becton Dickinson beat Q3 earnings and revenue estimates, raised its FY25 EPS outlook, and saw strong growth in its medical and interventional segments.

Thursday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.

Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?

Becton Dickinson (BDX) reported mixed Q3 2025 earnings, with revenue of $5.509B (+10.4% YoY) slightly missing estimates, while adjusted EPS of $3.68 beat forecasts. Stock rose 5.56% pre-market.

Medical technology company Becton, Dickinson and Company (NYSE:BDX) will be reporting earnings this Thursday before the bell. Here’s what you need to know.

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

Elevance Health and Waters led the weekly large-cap losers, hit by weak earnings, lowered guidance, and analyst downgrades.

Calm Before the Storm? Wall Street Holds Its Breath Ahead of Earnings and Inflation Bombshells

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q1, starting with BD (NYSE:BDX).

BD to spin off its diagnostics and biosciences business in a $17.5 billion merger with Waters, targeting $345 million in synergies by 2030.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Becton Dickinson stock (BDX): Signs point toward continued underperformance until early June 2027.